Searched for
TEVA PHARMA
Sun Pharma shares rally 9% in two days after $12-bn Organon deal. Here's what Morgan Stanley, other brokerages saySun Pharmaceutical Industries' shares surged nearly 9% after announcing the $11.75 billion acquisition of Organon & Co., a global leader in...- If Sun Pharma inspections come through, 2018 could be a turning point for Indian pharma: Amit Rajan, Prosfora Technology“We have to get our things in order for sterile manufacturing and Sun Pharma Halol plant is mostly on steriles.”
- DRL, Cipla, Aurobindo among others to buy products from TevaThe remedy requires Teva to divest the drug portfolio to 11 firms and marks the largest drug divestiture order in an FTC pharmaceutical mer...
- US court finds Teva's Copaxone patent invalid again: Natco PharmaNatco Pharma, a city-based drug maker, today said the US Court of Appeals for Federal Court has again found one of the patents of Teva's Co...
- Natco Pharma ends 5% higher as US Supreme Court invalidates rival Teva's patent for CopaxoneCopaxone (Glatiramer Acetate) is used in the treatment of relapsing-remitting multiple sclerosis.
- Teva’s hostile bid for Mylan: Deal could open up a $2-billion opportunity for pharma companiesAccording to experts, there is a possibility that the fruition of the deal will open up a $2-billion opportunity for Indian generic pharma ...
- Natco slumps; US court rules for Teva in drug patent caseUS Supreme Court sends patent case back to lower court. Generic launches by Natco and other pharma companies will be delayed, say analysts.
- Natco Pharma shares climb 7.5 per cent on boursesNatco's stock surged 7.50 per cent to settle at Rs 769.35 on the BSE. In intra-day trade, it soared 12.92 per cent to Rs 808.15.
- US Patents rejects Teva's plea on Copaxone; Natco shares upHyderabad-based Natco markets Copaxone (Glatiramer Acetate) -- used in the treatment of relapsing-remitting multiple sclerosis -- in the US...
- Natco Pharma rallies over 8% as US Court rejects stay request on CopaxoneShares of Natco Pharma surged higher after the US Supreme Court rejected rival Teva Pharma’s request for stay on Copaxone drug.
- Teva Pharma, P&G sets up OTC plant in GujaratIsrael-based Teva Pharmaceuticals, an $18 billion generic drug maker will set up OTC medicine facility in Gujarat in collaboration with Pro...
- Ex-Teva Frank Pieters to lead Cipla's European respiratory businessCipla, India's second-largest drug maker, has hired Teva's former vice-president Frank Pieters to spearhead its European respiratory busine...
- Natco Pharma loses patent case against Teva Pharmaceutical Industries of anti-sclerosis drugNatco Pharma has lost a patent litigation against Israel's Teva Pharmaceutical Industries in the US over multiple sclerosis treatment drug,...
- Wyeth makes $960 mn claims on Protonix patent case: Sun PharmaSun Pharma said US-based Wyeth Pharma has sought damages worth $960 mn related to their ongoing patent dispute over generic version of Prot...
- Lupin can't sell pill in US, Teva files patent suitIsraeli drugmaker Teva Pharma has filed a patent infringement suit in the US against Lupin that prevents the Indian pharma company from sel...
- Matrix drags Israeli co Teva to court over patent issueThe dust hasn’t settled yet on the Novartis case and another patent dispute has emerged in the pharma space.
- Teva, Glenmark call an end to patent disputeIsraeli generic major Teva and Mumbai-based Glenmark Pharmaceuticals have settled a patent dispute over various generic versions of Coreg -...
- Drug firms fight with foreign cos over patentsPharma companies are at loggerheads with their foreign counterparts over patent rights. Global pharma giants have been filing cases against...
- Teva’s protonix version sale in US to hit SunIn a development which may impact Sun Pharma’s hopes of a windfall by selling generic versions of Wyeth’s $2.5-billion drug Protonix.
- DRL expects verdict in Aciphex case by May 15As the patent clash between Dr Reddy's Labs (DRL) and Japanese pharma firm Eisai for the control over $1.3-billion anti-ulcer drug Aciphex ...
Load More
